Nymox Pharmaceutical Corporation
http://www.nymox.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Nymox Pharmaceutical Corporation
Finance Watch: Verona Accesses Up To $650m As Ensifentrine Approval Deadline Nears
Public Company Edition: Verona Pharma arranged up to $400m in new debt and up to $250m in revenue-related financing ahead of its COPD drug launch. Also, Organon, Sobi and Pacira priced $1bn, $275.1m and $250m note sales, respectively. Marinus, Emergent and Ginkgo cut jobs.
Deal Watch: Six Small Biopharma Mergers Reflect Recent Trend
M&A edition: Mergers by Century/Clade, Eliem/Tenet, Kintara/TuHURA, Aditxt/Appili, Onconova/Traws and Apotex/Searchlight follow other companies joining forces in a tight cash environment.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
Latigo Raises $135m To Channel Vertex
The start-up is aiming to develop a NaV1.8 inhibitor for pain, but previous efforts here have met with more failure than success.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Saliva-based Testing
- Urine-based Testing
- Other Names / Subsidiaries
-
- Nymox Corporation
- Nymox
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice